76 related articles for article (PubMed ID: 38499168)
1. Biologics for Psoriasis.
Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
[TBL] [Abstract][Full Text] [Related]
2. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
Thomas SE; Barenbrug L; Hannink G; Seyger MMB; de Jong EMGJ; van den Reek JMPA
Drugs; 2024 May; 84(5):565-578. PubMed ID: 38630365
[TBL] [Abstract][Full Text] [Related]
3. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
4. Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data.
Pinter A; Soliman AM; Manz KC; Weber V; Ludwig P; Mocek A; Höer A; Lebwohl MG
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1575-1585. PubMed ID: 38787476
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.
Takeshima R; Kamata M; Suzuki S; Ito M; Watanabe A; Uchida H; Chijiwa C; Okada Y; Azuma S; Nagata M; Egawa S; Hiura A; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Tada Y
J Dermatol; 2024 May; ():. PubMed ID: 38804254
[TBL] [Abstract][Full Text] [Related]
6. Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis.
Mattay SS; Zamani M; Saturno D; Loftus EV; Ciorba MA; Yarur A; Singh S; Deepak P
Clin Gastroenterol Hepatol; 2024 May; 22(5):961-970.e12. PubMed ID: 37821035
[TBL] [Abstract][Full Text] [Related]
7. Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004-2023).
Wang Y; Li J; Guo C; Yang G; Lin H; Zhang Y
J Dermatolog Treat; 2024 Dec; 35(1):2346282. PubMed ID: 38880492
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis.
Hjort G; Schwarz CW; Skov L; Loft N
JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38888917
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016-2022.
Bahr NC; Benedict K; Toda M; Gold JAW; Lipner SR
J Am Acad Dermatol; 2024 Jul; 91(1):119-122. PubMed ID: 38462134
[No Abstract] [Full Text] [Related]
10. [Translated article] Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice.
Berenguer-Ruiz S; Romero-Dávila M; Aparicio-Domínguez M; Olivares-Guerrero M; Daudén E; Llamas-Velasco M
Actas Dermosifiliogr; 2024 May; ():. PubMed ID: 38815679
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.
Tsai YC; Tsai TF
Ther Adv Musculoskelet Dis; 2017 Nov; 9(11):277-294. PubMed ID: 29344110
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics of Psoriasis Cases Treated by Biologics With an Extended Administration Interval: A Single-Center, Retrospective Observational Study.
Nozaki H; Honma M; Ishida-Yamamoto A
Cureus; 2024 May; 16(5):e59969. PubMed ID: 38854182
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical Eczematous Reaction in a Patient With IL-17 Inhibitor-Treated Psoriasis Vulgaris.
Brazen B; Colon J; Hobbs L; Nousari C
Cureus; 2024 May; 16(5):e60051. PubMed ID: 38854303
[TBL] [Abstract][Full Text] [Related]
14. Rapid response on facial psoriasis to bimekizumab: case series.
Bernardini N; Dattola A; Caldarola G; Orsini D; Assorgi C; D'Amore A; Maretti G; Richetta AG; Tolino E; Skroza N; Potenza C
Drugs Context; 2024; 13():. PubMed ID: 38817804
[TBL] [Abstract][Full Text] [Related]
15. Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.
Wallace RP; Refvik KC; Antane JT; Brünggel K; Tremain AC; Raczy MR; Alpar AT; Nguyen M; Solanki A; Slezak AJ; Watkins EA; Lauterbach AL; Cao S; Wilson DS; Hubbell JA
Cell Rep Med; 2024 Jan; 5(1):101345. PubMed ID: 38128533
[TBL] [Abstract][Full Text] [Related]
16. Biologics and Candidiasis Incidence: Minimally Rising Yeast.
Heymann WR
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38936665
[No Abstract] [Full Text] [Related]
17. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence.
Sun X; Cui Z; Wang Q; Liu L; Ding X; Wang J; Cai X; Li B; Li X
Autoimmun Rev; 2024 Apr; 23(4):103530. PubMed ID: 38499168
[TBL] [Abstract][Full Text] [Related]
18. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
